Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Confirmatory Trials: US FDA Expectations Become Clearer Amid FDORA Flexibilities

Jan 24 2025

• By Sue Sutter

2024/2025 Pink Sheet Perspectives — New FDA guidance offers more clarity about the timing of confirmatory trials. (Shutterstock)

Related Content

Accelerated Approval: US FDA Explains ‘Reasonably Likely’ Determination Criteria

Dec 05 2024

Confirmatory Trials: US FDA Toughens Stance On Need For Advance Planning, Due Diligence

Dec 06 2024

Accelerated Approval: Adcomm Should Always Precede Withdrawal Proposal, US FDA Says

Dec 09 2024

Accelerated Approval: US FDA Explains When A Confirmatory Trial Is ‘Underway’

Jan 06 2025

Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval

Mar 25 2024

FDORA Effect? For Accelerated Approval Class Of 2023, Most Confirmatory Trials At Least Underway

Jan 30 2024

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Apr 23 2024

Related Companies

Merck & Co., Inc.

Valneva SE

Iovance Biotherapeutics, Inc.

Gilead Sciences, Inc.

CymaBay Therapeutics, Inc.

Jazz Pharmaceuticals plc

Zymeworks, Inc.

Regeneron Pharmaceuticals, Inc.

Ipsen SA

Genfit SA

More from Pink Sheet Perspectives

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window